Skip to main content

Advertisement

SpringerLink
Log in

Update on prognostic factors in acromegaly: Is a risk score possible?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Certain clinical conditions and markers have recently been demonstrated to modify the natural history of acromegaly in affected patients. Thus, some clinical, histological, radiological and molecular factors are associated with more aggressive pituitary tumors that have higher biochemical activity, higher tumor volumes and decreased tumoral and biochemical responses to current therapies. However, these factors do not seem to have an equal influence on the prognosis of patients with acromegaly. We present a review of the factors that influence the clinical course of patients with acromegaly and propose a risk value for each factor that will allow prognostic scoring for affected patients by considering a combination of these factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93(1):61–67. doi:10.1210/jc.2007-1191

    Article  CAS  PubMed  Google Scholar 

  2. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613–1617

    Article  CAS  PubMed  Google Scholar 

  3. Lundin P, Eden Engstrom B, Karlsson FA, Burman P (1997) Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol 18(4):765–772

    CAS  PubMed  Google Scholar 

  4. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG (1994) Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73(5):233–240

    Article  CAS  Google Scholar 

  5. van der Lely AJ, Harris AG, Lamberts SW (1992) The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 37(2):181–185

    Article  Google Scholar 

  6. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152(3):379–387. doi:10.1530/eje.1.01863

    Article  CAS  PubMed  Google Scholar 

  7. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411–3418

    Article  CAS  PubMed  Google Scholar 

  8. Freda PU, Landman RE, Sundeen RE, Post KD (2001) Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 4(3):163–171

    Article  CAS  PubMed  Google Scholar 

  9. Parkinson C, Ryder WD, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86(11):5240–5244

    Article  CAS  PubMed  Google Scholar 

  10. Bando H, Sano T, Ohshima T, Zhang CY, Yamasaki R, Matsumoto K, Saito S (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39(4):355–363

    Article  CAS  PubMed  Google Scholar 

  11. Asa SL, Coschigano KT, Bellush L, Kopchick JJ, Ezzat S (2000) Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Am J Pathol 156(3):1009–1015. doi:10.1016/S0002-9440(10)64968-1

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P (1998) Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 83(5):1604–1610

    CAS  PubMed  Google Scholar 

  13. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67(15):7505–7511. doi:10.1158/0008-5472.CAN-07-0219

    Article  CAS  PubMed  Google Scholar 

  14. Frank SJ, Fuchs SY (2008) Modulation of growth hormone receptor abundance and function: roles for the ubiquitin–proteasome system. Biochim Biophys Acta 1782(12):785–794. doi:10.1016/j.bbadis.2008.06.001

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Haggstrom M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589–1597. doi:10.1210/jc.2011-2508

    Article  PubMed  Google Scholar 

  16. Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538. doi:10.1148/radiol.2282020695

    Article  PubMed  Google Scholar 

  17. Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978. doi:10.1210/jc.2010-0573

    Article  CAS  PubMed  Google Scholar 

  18. Turner HE, Wass JA (1999) Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1(3–4):147–151

    Article  CAS  PubMed  Google Scholar 

  19. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–106; discussion 106–107

  20. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93(7):2746–2750. doi:10.1210/jc.2008-0126

    Article  CAS  PubMed  Google Scholar 

  21. Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, Budka H (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163–171

    CAS  PubMed  Google Scholar 

  22. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2):103–113

    Article  CAS  PubMed  Google Scholar 

  23. DeLellis RA, Lloyd RV, Heitz PU, End C (eds) (2004) World Health Organization classification of tumors: tumours of endocrine organs. In: pp 10–47. IARC, Lyon

  24. Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39(5):758–766. doi:10.1016/j.humpath.2007.10.004

    Article  CAS  PubMed  Google Scholar 

  25. Hentschel SJ, McCutcheon E, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30(3):215–219

    Article  PubMed  Google Scholar 

  26. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679. doi:10.3171/jns.2003.99.4.0674

    Article  PubMed  Google Scholar 

  27. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D (1994) H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 78(4):842–846

    CAS  PubMed  Google Scholar 

  28. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D (1995) Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55(8):1613–1616

    CAS  PubMed  Google Scholar 

  29. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82(3):818–824

    CAS  PubMed  Google Scholar 

  30. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N (2010) Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett 31(6):823–828

    CAS  PubMed  Google Scholar 

  31. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW, Lioyd RV, Smyth HS, Barr A, Thorner MO, Gaylinn B, Laws ER Jr (1997) Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151(3):769–784

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373–E383. doi:10.1210/jc.2009-2556

    Article  PubMed  Google Scholar 

  33. Williams F, Hunter S, Bradley L, Chahal HS, Storr H, Akker SA, Kumar AV, Orme SM, Evanson J, Morrison PJ, Korbonits M, Atkinson AB (2013) Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J Clin Endocrinol Metab, jc20132868. doi:10.1210/jc.2013-2868

  34. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84(2):761–767

    Article  CAS  PubMed  Google Scholar 

  35. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94(11):4406–4413. doi:10.1210/jc.2009-0471

    Article  CAS  PubMed  Google Scholar 

  36. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4):536–543. doi:10.1111/j.1365-2265.2006.02630.x

    Article  Google Scholar 

  37. Sanchez-Tejada L, Sanchez-Ortiga R, Moreno-Perez O, Montanana CF, Niveiro M, Tritos NA, Alfonso AM (2013) Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinol Nutr 60(7):358–367. doi:10.1016/j.endonu.2012.09.005

    Article  CAS  PubMed  Google Scholar 

  38. Asa SL, Ezzat S (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2(11):836–849. doi:10.1038/nrc926

    Article  CAS  PubMed  Google Scholar 

  39. Wang Z, Melmed S (2000) Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275(11):7459–7461

    Article  CAS  PubMed  Google Scholar 

  40. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M (2008) Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 15(3):721–743. doi:10.1677/ERC-08-0012

    Article  CAS  PubMed  Google Scholar 

  41. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S (2000) Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275(25):18664–18669. doi:10.1074/jbc.M001615200

    Article  CAS  PubMed  Google Scholar 

  42. Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE, Wiesli P (2007) Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 53(8):1484–1488. doi:10.1373/clinchem.2007.085712

    Article  CAS  PubMed  Google Scholar 

  43. Mercado M, Gonzalez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E (2008) Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93(9):3411–3415. doi:10.1210/jc.2008-0391

    Article  CAS  PubMed  Google Scholar 

  44. Wassenaar MJ, Biermasz NR, Pereira AM, van der Klaauw AA, Smit JW, Roelfsema F, van der Straaten T, Cazemier M, Hommes DW, Kroon HM, Kloppenburg M, Guchelaar HJ, Romijn JA (2009) The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab 94(12):4671–4678. doi:10.1210/jc.2009-1172

    Article  CAS  PubMed  Google Scholar 

  45. Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavo S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea ML, Lania AG, Spada A (2012) Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 97(2):E165–E172. doi:10.1210/jc.2011-1769

    Article  CAS  PubMed  Google Scholar 

  46. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83(7):2286–2290

    Article  CAS  PubMed  Google Scholar 

  47. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50(3):637–642

    Article  CAS  PubMed  Google Scholar 

  48. Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2002) Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 359(9311):1036–1037. doi:10.1016/S0140-6736(02)08067-4

    Article  CAS  PubMed  Google Scholar 

  49. Bleumink GS, Rietveld I, Janssen JA, van Rossum EF, Deckers JW, Hofman A, Witteman JC, van Duijn CM, Stricker BH (2004) Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol 94(3):384–386. doi:10.1016/j.amjcard.2004.04.044

    Article  CAS  PubMed  Google Scholar 

  50. Miletta MC, Scheidegger UA, Giordano M, Bozzola M, Pagani S, Bona G, Dattani M, Hindmarsh PC, Petkovic V, Oser-Meier M, Fluck CE, Mullis PE (2012) Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency. Clin Endocrinol (Oxf) 76(5):683–690. doi:10.1111/j.1365-2265.2011.04267.x

    Article  CAS  Google Scholar 

  51. Akin F, Turgut S, Cirak B, Kursunluoglu R (2010) IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly. Growth Horm IGF Res 20(6):399–403. doi:10.1016/j.ghir.2010.09.001

    Article  CAS  PubMed  Google Scholar 

  52. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125–133. doi:10.1007/s11102-010-0269-9

    Article  CAS  PubMed  Google Scholar 

  53. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50(5):561–567. doi:10.1046/j.1365-2265.1999.00760.x

    Article  CAS  Google Scholar 

  54. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86(9):4072–4077

    Article  CAS  PubMed  Google Scholar 

  55. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF (2003) Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88(8):3567–3572

    Article  CAS  PubMed  Google Scholar 

  56. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58(1):86–91. doi:10.1046/j.1365-2265.2003.01679.x

    Article  Google Scholar 

  57. Salaun C, Foubert L, Vialatou M, Kujas M, Turpin G (1999) Prognostic factors in the surgical management of acromegaly. Ann Med Intern (Paris) 150(3):195–198

    CAS  Google Scholar 

  58. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87(10):4554–4563

    Article  CAS  PubMed  Google Scholar 

  59. Abe T, Sanno N, Osamura YR, Matsumoto K (1997) Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien) 139(7):613–618

    Article  CAS  Google Scholar 

  60. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138(12):1449–1455

    Article  CAS  Google Scholar 

  61. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47(6):1313–1318; discussion 1318–1319

  62. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93(8):2984–2990. doi:10.1210/jc.2008-0315

    Article  CAS  PubMed  Google Scholar 

  63. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661–666. doi:10.1530/EJE-09-0908

    Article  CAS  PubMed  Google Scholar 

  64. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57(12):1035–1044. doi:10.1507/endocrj.K10E-203

    Article  PubMed  Google Scholar 

  65. Colao A, Bronstein M, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely A, Farrall A, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab, jc20132480. doi:10.1210/jc.2013-2480

  66. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87(7):3013–3018

    Article  CAS  PubMed  Google Scholar 

  67. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863. doi:10.1210/jc.2004-1093

    Article  CAS  PubMed  Google Scholar 

  68. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G (1995) Effects of treatment with octreotide in acromegalic patients—a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133(4):430–439

    Article  CAS  PubMed  Google Scholar 

  69. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM et al (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117(9):711–718

    Article  CAS  PubMed  Google Scholar 

  70. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86(6):2779–2786

    CAS  PubMed  Google Scholar 

  71. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465–4473. doi:10.1210/jc.2005-0260

    Article  CAS  PubMed  Google Scholar 

  72. Lucas T, Astorga R, Catala M (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58(4):471–481. doi:10.1046/j.1365-2265.2003.01741.x

    Article  CAS  Google Scholar 

  73. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88(7):3090–3098

    Article  CAS  PubMed  Google Scholar 

  74. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91(6):2112–2118. doi:10.1210/jc.2005-2110

    Article  CAS  PubMed  Google Scholar 

  75. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599. doi:10.1210/jc.2006-2084

    Article  CAS  PubMed  Google Scholar 

  76. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297–303. doi:10.1007/s11102-009-0175-1

    Article  CAS  PubMed  Google Scholar 

  77. Duran-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagon MM, Culler MD, Barlier A, Castano JP (2010) A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 95(5):2497–2502. doi:10.1210/jc.2009-2247

    Article  CAS  PubMed  Google Scholar 

  78. Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 90(8):4824–4828. doi:10.1210/jc.2005-0132

    Article  CAS  PubMed  Google Scholar 

  79. Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76(1):96–102. doi:10.1111/j.1365-2265.2011.04163.x

    Article  CAS  Google Scholar 

  80. Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246. doi:10.1016/j.tem.2012.11.007

    Article  CAS  PubMed  Google Scholar 

  81. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295. doi:10.1210/jc.2005-0998

    Article  CAS  PubMed  Google Scholar 

  82. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92. doi:10.1210/jc.2005-1208

    Article  CAS  PubMed  Google Scholar 

  83. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133(6):686–690

    Article  CAS  PubMed  Google Scholar 

  84. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Bidlingmaier M, Strasburger CJ (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161(1):27–35. doi:10.1530/EJE-08-0910

    Article  CAS  PubMed  Google Scholar 

  85. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19–S24. doi:10.1530/EJE-09-0322

    Article  CAS  PubMed  Google Scholar 

  86. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF (2008) Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159(5):517–523. doi:10.1530/EJE-08-0205

    Article  CAS  PubMed  Google Scholar 

  87. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castano JP, Bernabeu I (2010) Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab. doi:10.1210/jc.2010-1742

    Google Scholar 

  88. Bernabeu I, Alvarez-Escola C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramirez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M (2010) The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95(1):222–229. doi:10.1210/jc.2009-1630

    Article  CAS  PubMed  Google Scholar 

  89. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L (2009) Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 12(3):196–199. doi:10.1007/s11102-008-0157-8

    Article  CAS  PubMed  Google Scholar 

  90. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007) Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10(1):53–59. doi:10.1007/s11102-007-0002-5

    Article  PubMed  Google Scholar 

  91. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of radiotherapy in acromegaly. Eur J Endocrinol 145(6):717–726. doi:10.1530/eje.0.1450717

    Article  CAS  PubMed  Google Scholar 

  92. Castinetti F, Morange I, Dufour H, Regis J, Brue T (2009) Radiotherapy and radiosurgery in acromegaly. Pituitary 12(1):3–10. doi:10.1007/s11102-007-0078-y

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Grant FISS 11/00161 to IB.

Author information

Authors and Affiliations

  1. Endocrinology Division, Servicio Gallego de Salud (SERGAS), Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, La Coruña, Spain

    E. Fernandez-Rodriguez, F. F. Casanueva & I. Bernabeu

  2. Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología, Obesidad y Nutrición, Instituto Salud Carlos III, 15706, Santiago de Compostela, Spain

    F. F. Casanueva

Authors
  1. E. Fernandez-Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. F. Casanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Bernabeu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Bernabeu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernandez-Rodriguez, E., Casanueva, F.F. & Bernabeu, I. Update on prognostic factors in acromegaly: Is a risk score possible?. Pituitary 18, 431–440 (2015). https://doi.org/10.1007/s11102-014-0574-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-014-0574-9

Keywords

Search

Navigation